Study of Actemura Remission induction of RA and Sequential Maintenance of Remission by Reasonable cost Treatment

Study of Actemura Remission induction of RA and Sequential Maintenance of Remission by Reasonable cost Treatment - STARR-SMARRT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012690

Enrollment

Registered

2013-12-27

Start date

2013-12-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

tocilizumab+tacrolimus+Bucillamine tocilizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.RA patients diagnosed by ACR/EULAR criteria(2010) 2.RA patients whose DAS28ESR is over 3.2 3.RA patients who have inadequate response to DMARDs 4.RA patients who is willing to participate in this study and signed the informed consent

Exclusion criteria

Exclusion criteria: 1.Patients with severe infection 2.Patients with active tuberclosis 3.Patients with malignancy 4.pregnant or breast-feeding

Design outcomes

Primary

Measure	Time frame
The low disease activity (DAS28ESR<3.2) maintenance rate after 24 weeks of TCZ treatment	—

Secondary

Measure	Time frame
The clinical remission (DAS28ESR<2.6) and the low disease activity (DAS28ESR<3.2) maintenance rate after 52 weeks of the clinical remission (DAS28ESR<2.6) maintenance rate - DAS28ESR transition - MMP-3 transition - HAQ-DI transition	—

Countries

Japan

Contacts

Public ContactRyutaro Matsumura

National hospital organization Chiba east national hospital Clinical Research Center

ryu-ma@ka2.so-net.ne.jp043-261-5171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026